Phase 3 AFFINE Trial
Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial
Actionable Insights Powered by AI
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial